These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 34304387)

  • 1. Mucosal Vaccine Delivery Using Mucoadhesive Polymer Particulate Systems.
    Cho CS; Hwang SK; Gu MJ; Kim CG; Kim SK; Ju DB; Yun CH; Kim HJ
    Tissue Eng Regen Med; 2021 Oct; 18(5):693-712. PubMed ID: 34304387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chitosan-based particulate systems for the delivery of mucosal vaccines against infectious diseases.
    Singh B; Maharjan S; Cho KH; Cui L; Park IK; Choi YJ; Cho CS
    Int J Biol Macromol; 2018 Apr; 110():54-64. PubMed ID: 29054527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers.
    Garg NK; Mangal S; Khambete H; Tyagi RK
    Recent Pat Drug Deliv Formul; 2010 Jun; 4(2):114-28. PubMed ID: 20380624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers.
    Mishra N; Goyal AK; Tiwari S; Paliwal R; Paliwal SR; Vaidya B; Mangal S; Gupta M; Dube D; Mehta A; Vyas SP
    Expert Opin Ther Pat; 2010 May; 20(5):661-79. PubMed ID: 20345332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Mucoadhesive Nanoparticle-Based Delivery System in the Development of Mucosal Vaccines.
    Zhao K; Xie Y; Lin X; Xu W
    Int J Nanomedicine; 2022; 17():4579-4598. PubMed ID: 36199476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymer nanotechnology based approaches in mucosal vaccine delivery: challenges and opportunities.
    Sharma R; Agrawal U; Mody N; Vyas SP
    Biotechnol Adv; 2015; 33(1):64-79. PubMed ID: 25499178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.
    Corthésy B; Bioley G
    Front Immunol; 2018; 9():431. PubMed ID: 29563912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nasal and pulmonary vaccine delivery using particulate carriers.
    Jia Y; Krishnan L; Omri A
    Expert Opin Drug Deliv; 2015 Jun; 12(6):993-1008. PubMed ID: 25952104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines.
    Jin Z; Gao S; Cui X; Sun D; Zhao K
    Int J Pharm; 2019 Dec; 572():118731. PubMed ID: 31669213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thermosensitive and mucoadhesive delivery systems of mucosal vaccines.
    Han IK; Kim YB; Kang HS; Sul D; Jung WW; Cho HJ; Oh YK
    Methods; 2006 Feb; 38(2):106-11. PubMed ID: 16414271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal vaccine design and delivery.
    Woodrow KA; Bennett KM; Lo DD
    Annu Rev Biomed Eng; 2012; 14():17-46. PubMed ID: 22524387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of mucoadhesive microspheres for the induction of mucosal and systemic immune responses.
    Kunisawa J; Okudaira A; Tsutusmi Y; Takahashi I; Nakanishi T; Kiyono H; Mayumi T
    Vaccine; 2000 Oct; 19(4-5):589-94. PubMed ID: 11027825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucoadhesive Vaccine Delivery Systems for the Oral Mucosa.
    Mokabari K; Iriti M; Varoni EM
    J Dent Res; 2023 Jul; 102(7):709-718. PubMed ID: 37148290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding Mucosal Physiology and Rationale of Formulation Design for Improved Mucosal Immunity.
    Biswas M; Nurunnabi M; Khatun Z
    ACS Appl Bio Mater; 2024 May; ():. PubMed ID: 38787767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments in nanocarrier-aided mucosal vaccination.
    Kammona O; Bourganis V; Karamanidou T; Kiparissides C
    Nanomedicine (Lond); 2017 May; 12(9):1057-1074. PubMed ID: 28440707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Uniqueness of the mucosal immune system for the development of prospective mucosal vaccine].
    Kunisawa J; Gohda M; Kiyono H
    Yakugaku Zasshi; 2007 Feb; 127(2):319-26. PubMed ID: 17268152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioadhesive delivery systems for mucosal vaccine delivery.
    Baudner BC; O'Hagan DT
    J Drug Target; 2010 Dec; 18(10):752-70. PubMed ID: 21039314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic polyacrylate polymers as particulate intranasal vaccine delivery systems for the induction of mucosal immune response.
    Zaman M; Simerska P; Toth I
    Curr Drug Deliv; 2010 Apr; 7(2):118-24. PubMed ID: 20158484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Microfold cells-targeting antigen delivery: a promising strategy to enhance the efficacy of mucosal vaccines].
    Wang Y; Li M; Sun Y; Qiu HJ
    Sheng Wu Gong Cheng Xue Bao; 2019 Feb; 35(2):216-225. PubMed ID: 30806051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ gelling and mucoadhesive polymers: why do they need each other?
    Zahir-Jouzdani F; Wolf JD; Atyabi F; Bernkop-Schnürch A
    Expert Opin Drug Deliv; 2018 Oct; 15(10):1007-1019. PubMed ID: 30173567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.